Key Highlights

  • Shares fell 12.70% to USD 1.07 in regular trading on November 3, 2026.
  • The prior close of about USD 1.23 implies a loss of USD 0.1557 (calculated).
  • The Halneuron Phase 2b trial completed enrollment of 239 patients, with topline data expected in November 2026.
  • Cash was USD 9.6 million at June 30, 2026, against USD 6.5 million at December 31, 2025.
  • A USD 5 million private Placement was announced on October 19, 2026 at USD 1.22 per share.

What Moved Dogwood Today (down USD 0.1557, 12.70%)

Dogwood Therapeutics (NASDAQ:DWTX) was down 12.70% to USD 1.07 in regular trading on November 3, 2026, compared with a Monday close of about USD 1.23 (calculated). The screen showed Volume of about 110.38K shares and a Market Capitalisation near USD 36.2 million.

No company announcement dated November 2 or November 3, 2026 was identified. The decline comes as the market waits for a binary trial readout, and traders often adjust positions in small biotechs ahead of such data, though that explanation is unconfirmed.

The Halneuron Trial and Funding Update

According to a company press release dated September 14, 2026, the randomized Phase 2b HAL-CINP trial completed enrollment at 239 patients, at the upper end of its planned range, with topline data expected in November 2026. The trial tests Halneuron against placebo in patients with moderate to severe neuropathic pain after platinum or taxane based chemotherapy, at about 25 U.S. sites.

Dosing is eight subcutaneous doses over 14 days with 28 days of follow up, and the primary endpoint is the change from baseline to week four in average daily pain intensity. On October 19, 2026 the company announced a USD 5 million private placement of 4,098,360 shares at USD 1.22 with its principal shareholder, which it said extends runway through March 2027.

Business Background and Recent Results

Dogwood is a clinical stage biopharmaceutical company developing treatments for pain and fatigue conditions, with Halneuron aimed at chemotherapy induced neuropathic pain, an area with limited non-opioid options. A 12 week open label extension has also begun for patients who finish the 4 week study.

For the second quarter of 2026, reported on August 13, the company posted a net loss of USD 11.5 million, or USD 0.34 per share, against USD 3.8 million a year earlier. The figure included a USD 9.2 million non-cash impairment, partly offset by a USD 2.5 million deferred tax benefit. Research and Development expense was USD 3.2 million against USD 2.6 million, and general and administrative expense was USD 1.6 million against USD 1.3 million.

Balance Sheet and Risks

The six month net loss was USD 16.5 million, against USD 14.7 million in the first half of 2025, and the Quarterly Report included Going Concern language. A shelf registration statement was filed on October 30, 2026, which can allow future share sales and carries dilution risk.

As a Penny Stock with a small market value, Dogwood can be highly volatile and thinly traded. Trial outcomes in a single indication can move such shares sharply in either direction.

What to Watch Next

The key event is the Halneuron Phase 2b topline readout, guided for November 2026. Investors will look at the size of the pain score difference against placebo and the safety profile.

Other markers include plans for a Phase 3 study, further financing after the shelf filing, and the next quarterly report with updated cash.